NEW YORK (GenomeWeb) — Biogazelle said today that it has received a €2 million ($2.5 million) investment from Qbic Arkiv Fund, Foundation Majoie, and SOFI (Spin-Off Financing Instrument).

Ghent, Belgium-based Biogazelle said that it will primarily use the investment to further develop its research on therapeutic RNA targets for specific cancer types and expand its commercial activities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.